11/8/26 Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Previous Learning More from Less: Smarter Design and Execution in Rare Disease Trials Next Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients You Might Also Like Write Your Own Endpoint Justification From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients Leveraging Natural History and RWE for Rare Approvals
11/8/26 Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Previous Learning More from Less: Smarter Design and Execution in Rare Disease Trials Next Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients You Might Also Like Write Your Own Endpoint Justification From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients Leveraging Natural History and RWE for Rare Approvals
